TY - JOUR
T1 - In vivo efficacy of the ketolide ABT-773 (cethromycin) against enterococci in a mouse peritonitis model
AU - Pai, Suresh R.
AU - Singh, Kavindra V.
AU - Murray, Barbara E.
PY - 2003/8/1
Y1 - 2003/8/1
N2 - Using six Enterococcus faecalis and five Enterococcus faecium strains, the ketolide ABT-773 (ABT), now known as cethromycin, was found to have in vivo efficacy against both erythromycin (ERY)-susceptible (Erys) and -intermediate (Eryi) enterococci (ABT 50% protective doses [PD50s], 0.5 to 4.1 and 10.3 to 16.2 mg/kg of body weight, respectively). Against four highly Ery-resistant (Eryr) strains for which ABT MICs were low, ABT showed much greater activity (PD50, 6.3 to 32.5 mg/kg) than ERY (PD50, >200 mg/kg) but was not protective for strains for which ABT MICs were high. In conclusion, ABT-773 showed in vivo efficacy and considerably greater activity than ERY in a mouse peritonitis model.
AB - Using six Enterococcus faecalis and five Enterococcus faecium strains, the ketolide ABT-773 (ABT), now known as cethromycin, was found to have in vivo efficacy against both erythromycin (ERY)-susceptible (Erys) and -intermediate (Eryi) enterococci (ABT 50% protective doses [PD50s], 0.5 to 4.1 and 10.3 to 16.2 mg/kg of body weight, respectively). Against four highly Ery-resistant (Eryr) strains for which ABT MICs were low, ABT showed much greater activity (PD50, 6.3 to 32.5 mg/kg) than ERY (PD50, >200 mg/kg) but was not protective for strains for which ABT MICs were high. In conclusion, ABT-773 showed in vivo efficacy and considerably greater activity than ERY in a mouse peritonitis model.
UR - http://www.scopus.com/inward/record.url?scp=0041767388&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0041767388&partnerID=8YFLogxK
U2 - 10.1128/AAC.47.8.2706-2709.2003
DO - 10.1128/AAC.47.8.2706-2709.2003
M3 - Article
C2 - 12878548
AN - SCOPUS:0041767388
SN - 0066-4804
VL - 47
SP - 2706
EP - 2709
JO - Antimicrobial Agents and Chemotherapy
JF - Antimicrobial Agents and Chemotherapy
IS - 8
ER -